particular are outperforming g heavily in in-house markets in aesthetic medicine. In elopment of new Advertorial May 2017, the Dermalfiller Princess the company’s @aestheticsgroup @aestheticsjournaluk Aesthetics aestheticsjournal.com Croma VOLUME was approved in China through innovation. by the CFDA. Croma-Pharma was roma also promotes the first European company to do maceutical research so. Almost at the same time, the more than 90% of company signed with Sihuan Pharma ed from products Becoming a global player with minimally invasive aesthetic medicine. ch.
Croma-Pharma: Made in Austria
ve
s re
tic d
e
New headquarters and production ntler Croma-Pharma GmbH, is an international pharmaceutical company based in plant as a clear commitment to free Leobendorf, Austria. For over 40 years, expansion and location ures Croma has been developing and producing Due to the dynamic development of the are so innovative drugs and medicalLtd. a for long-standing licenseand and devices company, the construction expansion of hat they can be distribution agreement. the fields of ophthalmology, orthopedics the headquarters andThis anotherjoint fully automatic a lunch venture the third-largest and break) aesthetic dermatology. Croma is very withproduction facility at the Leobendorf site was proud to have made such an important initiated in 2015. The new headquarters was ive the patient Chinese pharmaceutical company contribution to improving health and inaugurated in September ance. The expert is aimed at the approval of 2017. further quality of life for more than four decades. ferent technologies products and the nationwide Founded in 1976 by pharmacist Gerhard Innovations as a result of intensive and creates a longdistribution of these products in Prinz, Croma is now managed by his sons research and development or relationship. mainland Martin and Andreas Prinz. Since 2005, the China. Croma is investing heavily in in-house aesthetic medicine company has been driven forward through research and development of new products ge growth potential In 2014, Sustainability and social rapid internationalisation. the to drive the company’s long-term growth strategic sale of the Ophthalmology and through innovation. In this context, Croma uty market. In responsibility Orthopedics divisions took place, since then also promotes medical and pharmaceutical offers a steadily the company has specialised in minimally research in Austria. Today, more than 90% dinated portfolio As a family business, Croma invasive aesthetic medicine. Currently, of sales are generated from products of our goal is a “full-face pursues a corporate policy based Croma has 12 international offices in Brazil, own research. r doctors and on ecological, economic and social European Union and Switzerland and nearly solutions for allworldwide. sustainability. For many years, Croma 500 employees Aesthetic dermatology as a a single source in dynamic future market is sponsor of the international Leading HA expert in Europe aesthetic medicine, the trend ble quality. organizationIn modern “Light for the World”. Today Croma is a global player in the is moving from large, irreversible surgical With generous product donations dynamically growing segment of minimally lifts to smaller but more frequent, shorter Croma makes an important e course for invasive aesthetic medicine and is a leading and, above all, gentler treatments. Pain-free contributionlunchtime to the eye care in the S market European processor of hyaluronic acid. The procedures (treatments that are so poorest regions of the company sells nearly six million hyaluronic straightforward thatworld. they can be performed 8 Croma-Pharma acid syringes (injectables) annually through during a lunch break) are designed to affiliates and a network of strategic give the patient a relaxed appearance. stablishing a joint partnerships and distributors in more than 70 The expert combination of different with its long-time countries. Production takes place exclusively technologies optimises results and creates c. to develop and at the company headquarters in Leobendorf a long-term patient-doctor relationship. ulinum toxin, HA near Vienna, Austria. Besides a broad Minimally invasive aesthetic medicine has ead products in US, Contact above-average growth potential in the range of HA fillers from the own production a and New Zealand. site, Croma markets PDO lifting threads, global beauty market. In this area, Croma s its development GmbH a Platelet Rich Plasma (PRP) CROMA-PHARMA system and a offers a steadily growing, well coordinated in its coreHöhn portfolio of products. The goal is a ‘full-face tivitiespersonalised with a skincare technology Stefanie markets. orderstrategic to prepare Cromazeile 2approach’ to offer doctors and patients the e successful market A-2100 Leobendorf gic partnership Phone: +43 676 846868 190 Aesthetics | February 2020 ntinue Croma‘s Mail: stefanie.hoehn@croma.at
best solutions for all indications from a single source in familiar and reliable quality.
Croma sets the course for entering the US market In September 2019 Croma-Pharma GmbH (Croma) establishded a joint venture company with its long-time partner Hugel, Inc. to develop and commercialise botulinum toxin, HA filler and PDO thread products in US, Canada, Australia and New Zealand. Thus Croma unites its development and marketing activities with a strong partner in order to prepare and implement the successful market entry. The strategic partnership with Hugel will continue Croma‘s international expansion efforts and further strengthen Croma‘s market position.
Milestones product approval and joint venture in China Asia in general and China in particular are outperforming markets in aesthetic medicine. In May 2017, the dermal filler Princess VOLUME was approved in China by the CFDA. Croma-Pharma was the first European company to do so. Almost at the same time, the company signed with Sihuan Pharma Ltd. a long-standing license and distribution agreement. This joint venture with the thirdlargest Chinese pharmaceutical company is aimed at the approval of further products and the nationwide distribution of these products in mainland China.
Sustainability and social responsibility As a family business, Croma pursues a corporate policy based on ecological, economic and social sustainability. For many years, Croma has been the sponsor of the international organisation “Light for the World”. With generous product donations Croma makes an important contribution to eye care in the poorest regions of the world. Learn more about Croma’s products and services at croma.at Croma-Pharma GmbH Julian Popple: Country Manager UK Phone: +44 (0) 7442341 227 Email: julian.popple@cromapharma.com Orders: customerservice.uk@croma.at Website: www.croma.at This article is written and supported by Croma-Pharma 49
